Profit off the FDA’s Next Major Decision
Today I’m going to give you an inside look into what it’s like to be part of our elite trading group…
And of course, it all centers around an enormous winning trade.
Here’s the scoop…
Whenever I see fellow War Room members at financial shows or investment conferences, the winner that most often comes up in conversation is Biogen (BIIB).
In case you aren’t familiar with this trade, Biogen was waiting for a major FDA decision on a landmark Alzheimer’s drug candidate, and I recommended playing a two-sided call/put strangle to be ready for either an approval or a rejection.
Either one would’ve had tremendous consequences for the stock, which is why we got positioned to profit off an explosive move to the upside OR the downside.
As it turned out, Biogen ripped higher, which resulted in a huge winner for us. (It later ended up falling back down… but by then, it didn’t matter!)
The stock ended up being a roller coaster for most investors. But traders like us cleaned house off the intense volatility the day the news broke.
The reason I bring this up to you now is I think we could be facing a very similar situation with Vertex Pharmaceuticals (VRTX).
Here’s the rundown…
Just as BIIB had a groundbreaking drug candidate to treat Alzheimer’s, VRTX is currently developing what could be a groundbreaking drug in the area of pain relief.
The name of this drug candidate, VX-548, sounds like a droid from Star Wars – but that’s just how the FDA names these studies. All we need to know is this drug candidate could be a nonaddictive pain pill that eliminates the use of opioids.
No matter whether it’s prescribed after a tummy tuck or bunion surgery (which I hear can be quite painful), this new pain relief drug could truly be transformative for the entire medical industry. And it could be far more effective than the current treatment, which is essentially ibuprofen.
The results of three VRTX studies are expected to be announced either late this year or early next year, and the market reaction could be substantial.
According to Leerink Partners, sales of VX-548 could be over $5 billion if the study yields successful results. And according to Goldman Sachs analyst Salveen Richter, that could equate to a stock move of between $60 and $120, depending on the strength of the results.
YOUR ACTION PLAN
In this Wednesday’s issue of Trade of the Day Plus, I’ll be revealing the exact trade to get into right now to benefit regardless of whether VRTX soars or crashes based on the upcoming FDA decision. If you have any interest in receiving this trade, then you must sign up for Trade of the Day Plus right now. Join today, and you’ll get this new trade alert on Wednesday, November 8, after the market closes. It’ll be delivered straight to your email inbox in a unique and engaging video format.
P.S. If you make this trade, then the day this news breaks – no matter whether it’s good or bad – you’ll be properly positioned to cash in. Join today, and the pick will hit your inbox this Wednesday!
MONDAY MARKET MINUTE
- About Last Week… Wow! The market’s 5% jump last week, a response to the Fed’s era of interest rate hikes potentially being over, was borderline euphoric. How can we build on the best week since October 2022? That’s what we’ll be tracking this week.
- DraftKings Seeing More Upgrades. Almost every analyst following the company has either upgraded their target price or upgraded their rating of the shares. This includes MoffettNathanson analysts (led by Robert Fishman), who raised their call on DKNG stock from “Neutral” to “Buy.”
- Biotech Group Gets a Nod From Major Bank. Goldman Sachs initiated Legend Biotech (LEGN) as a “Buy,” calling the biotech company “best in class” thanks to its multiple myeloma drug, Carvykti.
- Some More Biotech Names Garnering Interest. According to InvestingChannel, some names seeing substantial increases in search activity include Altamira Therapeutics (CYTO), which has seen a 1,073% surge in interest, and InflaRX (IFRX), which has seen a 590% surge in interest.